Skip to main content
Erschienen in: Lung 6/2013

01.12.2013

PET–CT Evaluation of Solitary Pulmonary Nodules: Correlation with Maximum Standardized Uptake Value and Pathology

verfasst von: Yee Ting Sim, Yong Geng Goh, Mary Frances Dempsey, Sai Han, Fat Wui Poon

Erschienen in: Lung | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

18-fluorine fluorodeoxyglucose (18F-FDG) positron emission tomography–computed tomography (PET–CT) has an established role for the characterization of solitary pulmonary nodules (SPN). Visual assessment of nodule morphology, together with maximum standardized uptake value (SUVmax), is used to estimate likelihood of malignancy. We correlated SUVmax value with pathology of SPN and assessed diagnostic accuracy in differentiating malignant from benign nodule, using 2.5 as threshold SUVmax.

Methods

Retrospective review of PET–CT scans for SPN characterization between April 2008 and June 2011 was performed. Only cases with pathological verification were included.

Results

A total of 641 PET-CTs were performed for SPN characterization and staging; 186 patients (77 males, 109 females) with pathological confirmation were included, and 158 (85 %) nodules were malignant: adenocarcinomas (n = 66), squamous cell carcinomas (n = 40), and metastases (n = 20) were the commonest. 28 lesions (15 %) were benign, including granuloma/chronic inflammation (n = 8), infection (n = 7), and hamartomas (n = 5). Using cutoff SUVmax of 2.5, the accuracy of PET–CT in diagnosing malignant SPN is 81.2 %, with sensitivity 86.7 %, specificity 50 %, PPV 90.7 %, and NPV 40 %. The likelihood of malignancy increases with SUVmax. Nevertheless, even with SUVmax <2.5, there is a 62 % chance that a nodule is malignant.

Conclusions

Although PET–CT is useful in diagnostic workup of SPN, it cannot replace “gold standard” tissue diagnosis.
Literatur
1.
Zurück zum Zitat Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD (2003) The solitary pulmonary nodule. Chest 123(1 Suppl):89S–96SCrossRefPubMed Tan BB, Flaherty KR, Kazerooni EA, Iannettoni MD (2003) The solitary pulmonary nodule. Chest 123(1 Suppl):89S–96SCrossRefPubMed
2.
Zurück zum Zitat Gurney JW (1993) Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. theory. Radiology 186(2):405–413CrossRefPubMed Gurney JW (1993) Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. theory. Radiology 186(2):405–413CrossRefPubMed
3.
Zurück zum Zitat Midthun DE, Swensen SJ, Jett JR (1993) Approach to the solitary pulmonary nodule. Mayo Clin Proc 68:378–385CrossRefPubMed Midthun DE, Swensen SJ, Jett JR (1993) Approach to the solitary pulmonary nodule. Mayo Clin Proc 68:378–385CrossRefPubMed
4.
Zurück zum Zitat Lillington GA, Caskey CI (1993) Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 14:111–119PubMed Lillington GA, Caskey CI (1993) Evaluation and management of solitary and multiple pulmonary nodules. Clin Chest Med 14:111–119PubMed
5.
Zurück zum Zitat Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781CrossRefPubMed Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781CrossRefPubMed
6.
Zurück zum Zitat Erasmus JJ, Connolly JE, McAdams HP, Roggli VL (2000) Solitary pulmonary nodules: part 1. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 20:43–58CrossRefPubMed Erasmus JJ, Connolly JE, McAdams HP, Roggli VL (2000) Solitary pulmonary nodules: part 1. Morphologic evaluation for differentiation of benign and malignant lesions. Radiographics 20:43–58CrossRefPubMed
7.
Zurück zum Zitat Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K et al (2000) Lung nodule enhancement at CT: multicenter study. Radiology 214:73–80CrossRefPubMed Swensen SJ, Viggiano RW, Midthun DE, Muller NL, Sherrick A, Yamashita K et al (2000) Lung nodule enhancement at CT: multicenter study. Radiology 214:73–80CrossRefPubMed
8.
Zurück zum Zitat Jeong YJ, Lee KS, Jeong SY, Chung MJ, Shim SS, Kim H et al (2005) Solitary pulmonary nodule: characterization with combined wash-in and wash-out features by dynamic multidetector CT enhancement study. Radiology 237:675–683CrossRefPubMed Jeong YJ, Lee KS, Jeong SY, Chung MJ, Shim SS, Kim H et al (2005) Solitary pulmonary nodule: characterization with combined wash-in and wash-out features by dynamic multidetector CT enhancement study. Radiology 237:675–683CrossRefPubMed
9.
Zurück zum Zitat Lee KS, Yi CA, Jeong SY, Jeong YJ, Kim S, Chung MJ et al (2007) Solid or partly solid solitary pulmonary nodules: their characterisation using contrast wash-in and morphologic features at helical CT. Chest 131:1517–1526 Lee KS, Yi CA, Jeong SY, Jeong YJ, Kim S, Chung MJ et al (2007) Solid or partly solid solitary pulmonary nodules: their characterisation using contrast wash-in and morphologic features at helical CT. Chest 131:1517–1526
10.
Zurück zum Zitat Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914–924CrossRefPubMed Gould MK, Maclean CC, Kuschner WG, Rydzak CE, Owens DK (2001) Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA 285:914–924CrossRefPubMed
11.
Zurück zum Zitat Gould M, Fletcher J, Iannettoni MD (2007) Evaluation of patients with pulmonary nodules: when IS it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:108S–130SCrossRefPubMed Gould M, Fletcher J, Iannettoni MD (2007) Evaluation of patients with pulmonary nodules: when IS it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132:108S–130SCrossRefPubMed
12.
Zurück zum Zitat Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nuc Med 35(11):1771–1776 Lowe VJ, Hoffman JM, DeLong DM, Patz EF, Coleman RE (1994) Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nuc Med 35(11):1771–1776
13.
Zurück zum Zitat Al-Sugair A, Coleman RE (1998) Applications of PET in lung cancer. Semin Nucl Med 28(4):303–319CrossRefPubMed Al-Sugair A, Coleman RE (1998) Applications of PET in lung cancer. Semin Nucl Med 28(4):303–319CrossRefPubMed
14.
Zurück zum Zitat Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A (2009) Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 39:36–51CrossRefPubMed Basu S, Chryssikos T, Moghadam-Kia S, Zhuang H, Torigian DA, Alavi A (2009) Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med 39:36–51CrossRefPubMed
15.
Zurück zum Zitat Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P et al (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol (16)3:1075-1084 Lowe VJ, Fletcher JW, Gobar L, Lawson M, Kirchner P, Valk P et al (1998) Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol (16)3:1075-1084
16.
Zurück zum Zitat Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ (2006) Characterisation of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. Am J Roentgenol 187(5):1361–1367CrossRef Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ (2006) Characterisation of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. Am J Roentgenol 187(5):1361–1367CrossRef
17.
Zurück zum Zitat Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A et al (2006) Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 47:426–431PubMed Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A et al (2006) Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 47:426–431PubMed
18.
Zurück zum Zitat MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP et al (2005) Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 237(2):395–400CrossRefPubMed MacMahon H, Austin JH, Gamsu G, Herold CJ, Jett JR, Naidich DP et al (2005) Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 237(2):395–400CrossRefPubMed
19.
Zurück zum Zitat Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M et al (2007) Accuracy of PET–CT in characterization of solitary pulmonary lesions. J Nucl Med 48(2):214–220PubMed Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M et al (2007) Accuracy of PET–CT in characterization of solitary pulmonary lesions. J Nucl Med 48(2):214–220PubMed
20.
Zurück zum Zitat Yi CA, Lee KS, Kim BT, Choi JY, Kwon OJ, Kim H et al (2006) Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 47(3):443–450PubMed Yi CA, Lee KS, Kim BT, Choi JY, Kwon OJ, Kim H et al (2006) Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 47(3):443–450PubMed
21.
Zurück zum Zitat Nguyen NC, Kaushik A, Wolverson MK, Osman MM (2011) Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncol 50(5):670–677CrossRefPubMed Nguyen NC, Kaushik A, Wolverson MK, Osman MM (2011) Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study. Acta Oncol 50(5):670–677CrossRefPubMed
22.
Zurück zum Zitat Gupta NC, Graber GM, Bishop HA (2000) Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1–3 cm) and large (>3 cm) lymph node lesions. Chest 117(3):773–778CrossRefPubMed Gupta NC, Graber GM, Bishop HA (2000) Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1–3 cm) and large (>3 cm) lymph node lesions. Chest 117(3):773–778CrossRefPubMed
23.
Zurück zum Zitat Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43(9):1210–1217PubMed Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL (2002) Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 43(9):1210–1217PubMed
24.
Zurück zum Zitat Bar-Shalom R, Valdivia AY, Blaufox MD (2000) PET imaging in oncology. Semin Nucl Med 30(3):150–185CrossRefPubMed Bar-Shalom R, Valdivia AY, Blaufox MD (2000) PET imaging in oncology. Semin Nucl Med 30(3):150–185CrossRefPubMed
25.
Zurück zum Zitat de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF et al (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55(1):79–87CrossRefPubMed de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF et al (2007) Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 55(1):79–87CrossRefPubMed
26.
Zurück zum Zitat Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T et al (1998) Fluorine-18-FDG-PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39(6):1016–1020PubMed Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T et al (1998) Fluorine-18-FDG-PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 39(6):1016–1020PubMed
27.
Zurück zum Zitat Travis WD, Brambilla E, Noguchi M, Nicolson AG, Geisinger KR, Yatabe Y et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285PubMedCentralCrossRefPubMed Travis WD, Brambilla E, Noguchi M, Nicolson AG, Geisinger KR, Yatabe Y et al (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6(2):244–285PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417PubMed Zhuang H, Pourdehnad M, Lambright ES et al (2001) Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 42:1412–1417PubMed
29.
Zurück zum Zitat Barger RL, Nandalur KR (2012) Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol 19:153–158CrossRefPubMed Barger RL, Nandalur KR (2012) Diagnostic performance of dual-time 18F-FDG PET in the diagnosis of pulmonary nodules: a meta-analysis. Acad Radiol 19:153–158CrossRefPubMed
30.
Zurück zum Zitat Bryant AS, Cerfolio RJ (2006) The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 82:1016–1020CrossRefPubMed Bryant AS, Cerfolio RJ (2006) The maximum standardized uptake values on integrated FDG-PET/CT is useful in differentiating benign from malignant pulmonary nodules. Ann Thorac Surg 82:1016–1020CrossRefPubMed
Metadaten
Titel
PET–CT Evaluation of Solitary Pulmonary Nodules: Correlation with Maximum Standardized Uptake Value and Pathology
verfasst von
Yee Ting Sim
Yong Geng Goh
Mary Frances Dempsey
Sai Han
Fat Wui Poon
Publikationsdatum
01.12.2013
Verlag
Springer US
Erschienen in
Lung / Ausgabe 6/2013
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-013-9500-6

Weitere Artikel der Ausgabe 6/2013

Lung 6/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.